Galmed Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at HEP-DART 2025 Meeting

Galmed Pharmaceuticals has announced the acceptance of a late-breaking abstract for its lead drug candidate, Aramchol, at the HEP-DART 2025 Meeting. The abstract, titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib," will be presented with a poster on December 9. The research aims to enhance the effect of regorafenib in GI cancer models and has informed the initiation of a Phase 1/2 clinical trial of the combination of Aramchol and regorafenib in HCC and other GI cancers.